Treatment options for acute bipolar depression: an urgent unmet clinical need
- PMID: 37595995
- DOI: 10.1016/S2215-0366(23)00255-9
Treatment options for acute bipolar depression: an urgent unmet clinical need
Conflict of interest statement
MIH has been a scientific advisor to MindSet Pharma, Wake Network and Psyched Therapeutics. He has led contracted research for COMPASS Pathways Ltd. LNY has received personal fees from Alkermes, Allergan, GSK, Intracellular Therapies, Lundbeck, Merck, Otsuka, Sanofi, and Sunovion, and grants from AbbVie and Dainippon Sumitomo Pharma outside the submitted work; and serves as a board member for the Canadian Network for Mood and Anxiety Treatments.
Comment on
-
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.Lancet Psychiatry. 2023 Sep;10(9):693-705. doi: 10.1016/S2215-0366(23)00199-2. Lancet Psychiatry. 2023. PMID: 37595997
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
